### Highlights of This Issue 6333

#### SPECIAL FEATURES

**CCR Translations**

- **The Role of Protein Kinase CK2 in Glioblastoma Development**
  - Haitao Ji and Zhimin Lu
  - *See related article, p. 6484*

**CCR New Strategies**

- **New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons**
  - Radhe Mohan, Anita Mahajan, and Bruce D. Minsky

**Molecular Pathways**

- **Molecular Pathways: Protein Methyltransferases in Cancer**
  - Robert A. Copeland

**CCR Focus**

- **On Masterpieces and Breast Cancer Research**
  - Susan E. Bates

- **Progress in Breast Cancer: Overview**
  - Carlos L. Arteaga

- **Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer**
  - Aditya Bardia and José Baselga

- **Incorporating Genomics into Breast Cancer Clinical Trials and Care**
  - Adel Tabachy, Cynthia X. Ma, Ron Bese, and Matthew J. Ellis

- **Tackling the Diversity of Triple-Negative Breast Cancer**
  - Nicholas C. Turner and Jorge S. Reis-Filho

- **Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer**
  - Xiang H.-F. Zhang, Mario Giuliani, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne

- **Can Immunity to Breast Cancer Eliminate Residual Micrometastases?**
  - Mary L. Disis and Sasha E. Stanton

### HUMAN CANCER BIOLOGY

- **JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis**
  - Li Zhao, Wenjuan Li, Wen Zang, Zhifang Liu, Xia Xu, Han Yu, Qing Yang, and Jihui Jia

- **Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study**

- **Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer**
  - Takeshi Iwaya, Takeo Fukagawa, Yutaka Suzuki, Yusuke Takahashi, Genta Sawada, Masahisa Ishibashi, Junji Kurashige, Tomoya Sudo, Fumiyaki Tanaka, Kohie Shibata, Fumitaka Endo, Hirokatsu Katagiri, Koaru Ishida, Kohie Kume, Satoshi Nishizuka, Hisae Inuma, Go Wakabayashi, Masaki Mori, Mitsuru Sasako, and Koshi Mimori

- **PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival**
  - Hazel A. Rogers, Cerys Mayne, Rebecca J. Chapman, John-Paul Kilday, Beth Coyle, and Richard G. Grundy

---

**CNS Metastases in Breast Cancer: Old Challenge, New Frontiers**

- Nancy U. Lin, Lalith Amiri-Kordestan, Diane Palmieri, David J. Liewehr, and Patricia S. Steeg
CANCER THERAPY: PRECLINICAL

6461

1. Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma

Shih-Chi Su, Xiaoxiao Hu, Patrick A. Kenney, Megan M. Merrill, Kara N. Babaian, Xiu-Ying Zhang, Tapati Maity, Shun-Fa Yang, Xin Lin, and Christopher G. Wood

6473

2. Cidofovir: A Novel Antitumor Agent for Glioblastoma

Piotr Hadaczek, Tomoko Ozawa, Liliana Soroceanu, Yasuyuki Yoshida, Lisa Matlaf, Eric Singer, Estefania Fiallos, C. David James, and Charles S. Cobbs

6484

3. Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma

Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo Kim, Markus Bredel, and Etty N. Benveniste

See related article, p. 6335

6495


Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hiroyuki Kishimoto, Futoshi Uno, Takeshi Nagasaka, Yasuo Urata, Shunsuke Kagawa, Robert M. Hoffman, and Toshiyoshi Fujiwara

6506

5. Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models

Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, and Eunice S. Wang

6520

6. The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low JuxExpression

Marion A. Salvador, Julien Wicinski, Olivier Cabaud, Yves Toiron, Pascal Finetti, Emmanuelle Josselin, Hélène Lelièvre, Laurence Kraus-berthier, Stéphane Depil, François Bertucci, Yves Collette, Daniel Birmbaum, Emmanuelle Charafé-Jauffret, and Christophe Ginestier

IMAGING, DIAGNOSIS, PROGNOSIS

6544

Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer


6556

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma


CANCER THERAPY: CLINICAL

6578

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112)

Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Robert L. Coleman, Michael Frumovitz, and Anil K. Sood
Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer
Patrick J. Schuler, Malgorzata Harasymczuk, Bastian Schilling, Zenichiro Saze, Laura Strauss, Stephan Lang, Jonas T. Johnson, and Theresa L. Whiteside

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Jobe, Robert M. Conry, Ahmad A. Tarihi, and John M. Kirkwood

Photodynamic Therapy with 3-(1’-Hexyloxyethyl) Pyropheophorbide α for Cancer of the Oral Cavity
Nestor Rigual, Gal Shafirstein, Michele T. Cooper, Heinz Baumann, David A. Bellnier, Ulas Sunar, Erin C. Tracy, Daniel J. Rohrbach, Gregory Wilding, Wei Tan, Maureen Sullivan, Mihai Merzianu, and Barbara W. Henderson

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K. Jain, Francis W. Nugent, Dan G. Duda, and Keith Stuart

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Quantification of Excision Repair Cross-Complementing Group I and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Ranee Mehra, Fang Zhu, Dong-Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra K. Singh, Anna S. Nikonova, Erica A. Golemis, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, and Barbara Burtness

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a human U251-MG glioblastoma cell transfected with 100 nM of non-target siRNA. Phalloidin (green) and DAPI (blue) staining shows organized F-actin and cell morphology. For details, see the article by Zheng and colleagues on page 6484 of this issue.